Publications
-
Cytokine-Induced Killer Cell Therapy as a Postremission Strategy in High-Risk Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Prospective Investigator-Initiated Clinical Study
- Publication information
- Transplant Cell Ther. 2026 Apr;32(4):448.e1-448.e16. doi: 10.1016/j.jtct.2026.01.001.
-
Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study
- Publication information
- Clin Infect Dis. 2026 Feb 4;81(6):e510-e514. doi: 10.1093/cid/ciaf302.
-
SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants
- Publication information
- Int J Mol Sci . 2024 Sep 29;25(19):10512.
-
Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study
- Publication information
- Int J Mol Sci. 2024 Jun 19; 25(12): 6731
-
Mesenchymal Stem Cells Preconditioned with a TLR5 Agonist Enhanced Immunoregulatory Effect Through M2 Macrophage Polarization in a Murine Graft-versus-Host Disease Model
- Publication information
- Int J Med Sci. 2024 Jun 17; 21(9):1649-1660
-
The IL-6 Signaling Pathway Contributes Critically to the Immunomodulatory Mechanism of Human Decidua-Derived Mesenchymal Stromal Cells
- Publication information
- iScience. 2024 Apr 18; 27(5): 109783
-
TLR5 Agonist in Combination with Anti-PD-1 Treatment Enhances Anti-Tumor Effect Through M1/M2 Macrophage Polarization Shift and CD8+ T Cell Priming
- Publication information
- Cancer Immunol Immunother . 2024 Apr 17;73(6):102.
-
Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment
- Publication information
- Front. Immunol., 23 December 2021
-
Human Mesenchymal Stem Cells Derived From Umbilical Cord and Bone Marrow Exert Immunomodulatory Effects in Different Mechanisms
- Publication information
- World J Stem Cells. 2020 Sep 26;12(9):1032-1049.
-
Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model.
- Publication information
- Stem Cells Dev. 2019 Jan 15;28(2):129-140.
-
Infusions of Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes as Post-Remission Therapy in High-Risk Post-Transplant Lymphoproliferative Disorder Patients: Report of Two Cases.
- Publication information
- Int J Hematol. 2018 May;107(5):596-603.
-
Robust Production of Cytomegalovirus PP65-Specific T cells Using a Fully Automated IFN-g Cytokine Capture System.
- Publication information
- Transfus Med Hemother. 2018 Jan;45(1):13-22.
-
Third-Party Regulatory T Cells Prevent Murine Acute Graft-versus-Host Disease.
- Publication information
- Korean J Intern Med. 2017 Oct 19. doi: 10.3904/kjim.2016.319
-
Alternative Approaches to Preserve MSC Progenitor Potency.
- Publication information
- Blood Res. 2017 Mar;52(1):1-2. doi: 10.5045/br.2017.52.1.1. Epub 2017 Mar 27.
-
Enhanced Immunoregulation of Mesenchymal Stem Cells by IL-10-Producing Type 1 Regulatory T Cells in Collagen-Induced Arthritis.
- Publication information
- Scientific reports 2016;6:2685
-
Therapeutic Potential of Low-Dose IL-2 in a Chronic GVHD Patient by In Vivo Expansion of Regulatory T Cells.
- Publication information
- Cytokine 2016;78:22-26.
-
Overcoming Immunoregulatory Plasticity of Mesenchymal Stem Cells for Accelerated Clinical Applications.
- Publication information
- International journal of hematology 2016;103:129-137.
-
Il-21-Expressing Mesenchymal Stem Cells Prevent Lethal B-Cell Lymphoma Through Efficient Delivery of IL-21, Which Redirects the Immune System to Target the Tumor.
- Publication information
- Stem cells and development 2015;24:2808-2821.
-
Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD model.
- Publication information
- PloS one 2015;10:e0138846.
-
Long-Term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated with Post-Remission Therapy Using EBV LMP1 and LMP2a-Specific CTLs.
- Publication information
- Molecular therapy : the journal of the American Society of Gene Therapy 2015;23:1401-1409.
